SingHealth Duke-NUS Academic Medical Centre will NEVER ask you to transfer money over a call. If in doubt, call the 24/7 ScamShield helpline at 1799, or visit the ScamShield website at www.scamshield.gov.sg.

IRB Submissions & Review Fees

Synonym(s):

Initial Application

Research studies requiring IRB approval must be submitted via ECOS for review. No research activities may be carried out prior to the approval.

An overview of the initial application submission and review process is as follows. 

20240229-IRB-Application-Form-Submission-and-Review-Workflow.png

 

For the initial application, once the form has been declared by the Principal Investigator (PI), it will be automatically routed to the Research Office Checker (ROC) if applicable, Department Representative (DR) and subsequently, the Institution Representative (IR) for endorsement. After which, the form will be submitted to the CIRB.

Once submitted a preliminary review will be conducted on the completeness of the submission and suitability of the review type. For studies that require exemption and expedited review, they will be reviewed by the Board Chairperson. For studies that require full board review, they will be reviewed at the monthly convened meetings at which a quorum is present. Notifications of approval or revisions will be communicated via auto-generated mails from the system.

The review type is determined based on the level of risk in which research participants are exposed to. The determination of the type of review is to be made by CIRB. Below is a summary of the information.

 
  Exempted Review Expedited Review Full Board Review3
Exemption Category One of the exemption category S1-5 must be met N.A N.A
Risk1 Minimal/ less than minimal risk Minimal/ less than minimal risk More than minimal risk
Submission Deadline Submitted anytime Submitted anytime First working day of the month (except December)4
Review Timeline2 30 working days from date of receipt 30 working days from date of receipt 60 working days from date of receipt
 
Note:
1Minimal risk is defined as "the probability and magnitude of harm or discomfort anticipated in the research are not greater than those ordinarily encountered in daily life, or during the performance of routine physical or physiological examinations or tests."
2This could vary depending on several factors such as the completeness, and quality of the application, complexity of the study and response time to CIRB's queries.
3A study that is minimal/ less than minimal risk may be tabled for Full Board Review when the study involves novel procedures/ interventions/ methodologies and/or does not qualify for Expedited Review.
4For Studies under the Green Lane Review, please refer to the FAQ for the submission deadline. 
 

Full Board Meeting Dates

The Board will conduct full board review at a convened meeting monthly (with the exception of the month of December) wherein a quorum is present. A quorum is defined as five members including the Chairperson (a medical practitioner), at least one external Scientific Member and one external Lay Member.
 
*The Green Lane Review Board will conduct bi-monthly meeting (including the month of December)
 
Applications should be submitted with sufficient lead time for the ROC to check if applicable, and for the DR and IR to endorse. A preliminary review to evaluate the completeness of the submitted application will be conducted. This may include requests for additional information and clarifications. Applications received after the first working day or delay in the reply may result in the application being tabled for the subsequent full board meeting.
 
If you anticipate that your IRB application will require full board review, please observe the submission deadline.
 
Note:
For CIRB A to F: Submission deadline for full board review is the 1st working day of the month with the exception of the month of December as there is no full board meeting. Principal investigators are advised to submit a complete application on time or in advance before the submission deadline.
For Green Lane Review: Submission deadline for full board review is 1st and 3rd Monday of the month. Principal investigators are advised to submit a complete application on time or in advance before the submission deadline.
 
Meeting Dates for 2026
  A B C D E F Green Lane Review
Jan 23 Jan 15 Jan 21 Jan 16 Jan 15 Jan 20 Jan -
Feb 20 Feb 26 Feb 25 Feb 20 Feb 26 Feb 24 Feb -
Mar 20 Mar 19 Mar 18 Mar 27 Mar 26 Mar 24 Mar -
Apr 17 Apr 28 Apr 15 Apr 17 Apr 16 Apr 21 Apr 14 Apr
28 Apr
May 15 May 26 May 20 May 15 May 14 May 19 May 12 May
26 May
Jun 19 Jun 23 Jun 17 Jun 26 Jun 18 Jun 23 Jun
09 Jun
23 Jun
Jul 17 Jul 28 Jul 15 Jul 17 Jul 16 Jul 21 Jul 14 Jul
28 Jul
Aug 21 Aug 25 Aug 19 Aug 21 Aug 20 Aug 18 Aug 11 Aug
25 Aug
Sep 25 Sep 22 Sep 16 Sep 18 Sep 17 Sep 15 Sep 08 Sep
22 Sep
Oct 16 Oct 27 Oct 21 Oct 16 Oct 15 Oct 20 Oct 13 Oct
27 Oct
Nov 20 Nov 24 Nov 18 Nov 20 Nov 19 Nov 17 Nov 10 Nov
24 Nov
Dec - - - - - - 08 Dec
22 Dec
 
Kindly note that the above timetable is correct as of 24 Feb 2026 and may be subject to change without prior notice.
 
Amendment / Exemption Amendment Form

The CIRB should be notified of any changes made to the approved applications. No implementation of the changes may be carried out without prior approval. All requests for modification are reviewed by an expedited review procedure unless there have been major changes to the approved applications where the risk/benefit ratio is altered.

For exempted studies, unless the changes made alter the exempt status, amendment submission is not required.

The amendment form is not required to go through the endorsement process unless the following changes are made to the approved application.
• Change in PI/ Site-PI
• Addition of study site(s)
• Significant changes to protocol
• Changes in form type

All amendment request should be submitted via ECOS for review. The amendment consists of two parts:
1. Study Amendment Cover Note: To identify the reason for the amendment
2. Amendment Form: To edit the sections and study documents to reflect the requested changes.

The amendment can initiated in ECOS by any study team member listed in the approved application. After filling the amendment cover note, the system will create the amendment form by copying the approved application/ the last approved amendment form, and opening a copy for editing. The required changes can then be made and submitted to the IRB for review.

The submission process is as follows.

Amendment submission.png

Please note that the form can only be submitted by the PI and only one amendment form can be submitted at any one time.

Study Status Report Form

The study status report form is to be used for the following purpose:
1. Study Renewal
2. Study Status Update
3. Study Reactivation
4. Study Closure
 
Study Renewal

The approval period granted by CIRB for approved applications is one year (12 months). For research studies which will continue beyond one year, the PI must submit a request for renewal via ECOS. It is the responsibility of the PI to submit the study status report form with sufficient time prior to the expiration of the current IRB approval, so that no lapse in the study approval occurs. It is recommended for the form to be submitted at least 2 months (60 days) before the expiry.

Note: In the event where the approval has lapsed, both the study status report form and study deviation/non-compliance report form have to be submitted to CIRB.

ECOS will send email and system notifications beginning 3 months (90 days) before the study expiration. The notifications sent are as follows.

• 1st Study Expiry Reminder – 90 days prior to expiry of ethics approval
• 2nd Study Expiry Reminder – 60 days prior to expiry of ethics approval
• Final Study Expiry Notification – 30 days prior to expiry of ethics approval

Continuing review of expedited or full board approved applications will be conducted with the same diligence as utilised during the initial review of the research. Continuing review of full board approved applications may be considered for expedited review if (i) the research is permanently closed to the enrolment of new participants, all participants have completed all research-related interventions and the research remains active only for long-term follow-ups, (ii) no participants have been enrolled and no additional risks have been identified or (ii) the remaining research activities are limited to data analysis. For exemption studies, the requirement for continuing review is waived.

All renewal requests should be submitted via ECOS for review.

Study Status

Study Status Update should be used when there is an update to the study status. For example, change of study status from “ongoing” to “suspended”. Study Status Update can be submitted at any time.

Study Reactivation

The study reactivation is to be used to re-open a research study which is previously closed or where the approval has lapsed. All studies must retain an active IRB approval in order for research activities to be carried out. Otherwise, all research activities, including screening, enrolment, interventions, and interactions and collection of data and samples, or analysis of data and samples that have already been collected, or use of study data must stop.

Review of the form will be conducted with the same diligence as utilised during the initial review of the research

Study Closure

The study closure is to be used for the reporting of study closure, termination or withdrawal. The form is to be submitted to CIRB via ECOS within the following timeframe.

Study Closure – Within 30 days
The study may be completed when all research-related interventions or interactions with participants have been completed and data analysis involves only unidentifiable data. For multi-site studies, the study may be closed regardless of the completion status of the global study.

Study Termination – Within 7 days
The study may be terminated by the PI, Institution or sponsor if the study is stopped after IRB approval.

The submission process for the study status report forms is as follows.

Study Closure form.png

Please note that the form can only be submitted by the PI and only one study renewal form can be submitted at any one time.

Study Deviation & Non-Compliance Report Form

All PIs and the study teams are responsible for reporting information regarding the approved study in a timely manner, understanding and adhering to the reporting timeline.

Any incidence of unplanned excursion from the approved protocol (i.e. deviation) or failure to abide by the CIRB and other applicable regulatory requirements (i.e. non-compliance) should be reported to the CIRB via ECOS as soon as possible but not later than 14 calendar days after 1st knowledge by PI using the Study Deviation/Non-compliance Report form.

The submission process for the study deviation & non-compliance report forms is as follows.

Protocol-deviation.png

Please note that the form can only be submitted by the PI. Multiple study deviation & non-compliance report form can be submitted at any one time.

Serious Adverse Event (SAE) Report Form

All PIs and the study teams are responsible for reporting information regarding the approved study in a timely manner, understanding and adhering to the reporting timeline.

Any serious untoward medical occurrence in participants recruited by any study site that is reviewed by CIRB constitutes a local SAE. Submission of SAE occurred in study sites that is not reviewed by CIRB constitutes non-local SAE (overseas SAE). Both local and non-local SAE should be reported to the CIRB via ECOS using the SAE Report Form. The reporting timeline is available under the "Guidelines" section of the "Forms & Resources" page.

The submission process for the SAE report forms is as follows.

LSAE report.png

Please note that the form can only be submitted by the PI, Site-PI and Co-I. Multiple SAE report forms can be submitted at any one time.

Other Study Notification (OSN) Report Form

The OSN Report Form is to be used to report to CIRB on the following:

• DSMB Report

• Annual/Interim /Periodic Safety Report

• Interim Data Analysis

• Letter from Study Sponsors

• Other Notification

The submission process for the OSN report forms is as follows.

ORE form.png

Please note that the form can only be submitted by the PI. Multiple OSN report forms can be submitted at any one time.

IRB Review Fees

Effective from 1 April 2025, for studies initiated by industry or commercial entities, the following review fee would be charged:

• Initial application review involving institution(s) from only one healthcare cluster: S$3,000
• Initial application review involving institution(s) from two healthcare clusters: S$4,000
• Initial application review involving institution(s) from three healthcare clusters: S$5,000
• Subsequent amendments (involving protocol and/or informed consent document amendments): S$300
• Subsequent addition of first site from another healthcare cluster: S$1,000/cluster
• Renewal for submission of study renewal/study reactivation report form: S$1,000

Note:

1. All charges stated above are subjected to prevailing GST.

2. Review fees should be paid and proof of payment should be included at the time of submission.      

- Please attach the proof of payment in the Other Attachments section of the Application, Amendment and Study Status Report Forms.       

- When making payment, include ‘CIRB and [ECOS Form Reference]’ in the PayNow or TT/Giro transaction details, e.g. CIRB 2023-1000-APP1.       

- An invoice would be issued to acknowledge receipt of the review fee and would be sent to the contact person listed in the CRMS>IRB Review Fees Billing Details.

 
Payment options
 
1. PayNow
Scan QR code or use UEN Proxy: 198702955E13S
 
2. TT/Giro Payment
Bank Account Name: Singapore Health Services PL CO MOHH
Bank Account Number: 8858131403
Bank Name: DBS Bank Ltd
Bank Address: 12 Marina Boulevard, Level 45, Marina Bay Financial Centre, Tower 3, Singapore 018982
Swift Code: DBSSSGSG
Bank code: 7171
Branch code: 003